Two molecular control factors play a decisive role in what is known as splicing, the cutting and assembly of mature messenger ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

Tuesday will be Tom Cech Day throughout the city of Champaign — and the distinguished honoree will be in town for the ...

In the microscopic world of bacteria, gene transfer is a powerful mechanism that can alter cellular function, drive antibiotic resistance and even shape entire ecosystems. Now an interdisciplinary ...

The Rice team's new method, called RNA-addressable modification (RAM), bypasses these hurdles by using a synthetic catalytic RNA (cat-RNA) to "barcode" ribosomal RNA (rRNA) inside living cells. By ...

In the microscopic world of bacteria, gene transfer is a powerful mechanism that can alter cellular function, drive antibiotic resistance and even shape entire ecosystems.

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

BMO Capital Markets initiates coverage on Dyne Therapeutics with an Outperform rating, an $84 target, and a projected $4.3 ...

ARO-C3 showed a maximum mean C3 reduction of 89% and sustained reduction over 87% through 24 weeks in a Phase 1/2 study. The therapy reduced proteinuria, with a mean UPCR drop of 41% and a maximum ...